ArticleMedicine2026
Enarodustat combined with oral iron supplementation for iron-deficient non-dialysis-dependent chronic kidney disease anemia patients: Synergistic effects and safety.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the synergistic effect and safety of enarodustat combined with oral iron supplementation in the treatment of iron-deficient non-dialysis-dependent chronic kidney disease (NDD-CKD) patients with anemia. This single-center retrospective cohort study enrolled 120 iron-deficient NDD-CKD patients with anemia who had not received erythropoiesis-stimulating agents or intravenous iron within the preceding month. According to the treatment protocols administered, the participants were divided into a combination therapy group (n = 64) and a monotherapy group (n = 56). The combination therapy group (n = 64) received enarodustat combined with ferrous succinate sustained-release tablets, while the monotherapy group (n = 56) received ferrous succinate sustained-release tablets alone. Patients were followed for 8 weeks to evaluate hemoglobin (Hb) levels, iron metabolism parameters, erythropoietic parameters, and adverse events. After 8 weeks of treatment, Hb levels in the combination therapy group were significantly higher than those in the monotherapy group (P < .05). The achievement rate of Hb ≥ 100 g/L was 82.81% in the combination group versus 57.14% in the monotherapy group (P < .01); the achievement rate of Hb ≥ 110 g/L was 62.50% and 44.64%, respectively (P < .05). Serum ferritin, transferrin saturation, and serum iron in the combination therapy group were all significantly higher than those in the monotherapy group (all P < .001). The increase in reticulocyte count and hematocrit was more pronounced in the combination group (P < .001), while red blood cell count showed a numerical increase without reaching statistical significance. There was no significant difference in the overall incidence of adverse events between the 2 groups (P > .05), and no serious adverse events occurred in either group. This study indicates that enarodustat combined with oral iron supplementation may have a certain synergistic effect on iron-deficient NDD-CKD anemia compared with oral iron alone, potentially helping to improve hematological indicators and promote erythropoiesis, with an acceptable safety profile. This combined regimen may provide a preliminary reference for the management of NDD-CKD anemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.